(Q37855722)

24 August 2017

1 reference

title

Multiple sclerosis therapeutic pipeline: opportunities and challenges (English)

1 reference

24 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Stephen Krieger

1

1 reference

24 August 2017

publication date

1 March 2011

1 reference

Mount Sinai Journal of Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

78

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

192-206

1 reference

Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies

24 August 2017

cites work

1 reference

Emerging oral therapies in multiple sclerosis

21 January 2018

1 reference

Treating multiple sclerosis with monoclonal antibodies: a 2010 update.

21 January 2018

1 reference

Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis

21 January 2018

1 reference

Compliance, adherence, and the treatment of multiple sclerosis

21 January 2018

1 reference

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis

21 January 2018

1 reference

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

Dose comparison trial of sustained-release fampridine in multiple sclerosis

21 January 2018

1 reference

Fingolimod for relapsing multiple sclerosis: an update.

21 January 2018

1 reference

Emerging multiple sclerosis oral therapies

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

21 January 2018

1 reference

Pathophysiology of multiple sclerosis and the place of teriflunomide

21 January 2018

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Monoclonal antibodies in MS: mechanisms of action

21 January 2018

1 reference

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

Role of B cells in pathogenesis of multiple sclerosis

21 January 2018

1 reference

Multiple sclerosis: new treatment trials and emerging therapeutic targets

21 January 2018

1 reference

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Treating multiple sclerosis with monoclonal antibodies

21 January 2018

1 reference

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.

21 January 2018

1 reference

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

Melanoma following treatment with alemtuzumab for multiple sclerosis.

21 January 2018

1 reference

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis

21 January 2018

1 reference

Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience.

21 January 2018

1 reference

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations

21 January 2018

1 reference

Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design

21 January 2018

1 reference

Fingolimod is a potential novel therapy for multiple sclerosis

21 January 2018

1 reference

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

21 January 2018

1 reference

LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MSJ.20241

1 reference

24 August 2017

1 reference